

SKADDEN, ARPS, SLATE, MEAGHER & FLOM LLP

1440 NEW YORK AVENUE, N.W.
WASHINGTON, D.C. 20005-2111

TEL: (202) 371-7000

FAX: (202) 393-5760

www.skadden.com

FIRM/AFFILIATE OFFICES

BOSTON
CHICAGO
HOUSTON
LOS ANGELES
NEW YORK
PALO ALTO
WILMINGTON

BEIJING
BRUSSELS
FRANKFURT
HONG KONG
LONDON
MOSCOW
MUNICH
PARIS
SÃO PAULO
SEOUL
SHANGHAI
SINGAPORE
TOKYO
TORONTO

DIRECT DIAL
202-371-7233
DIRECT FAX
202-661-8280
EMAIL ADDRESS
MARC.GERBER@SKADDEN.COM

BY EMAIL (shareholderproposals@sec.gov)

January 15, 2021

U.S. Securities and Exchange Commission
Division of Corporation Finance
Office of Chief Counsel
100 F Street, N.E.
Washington, D.C. 20549

RE: Assembly Biosciences, Inc. – 2021 Annual Meeting
Omission of Shareholder Proposal of James McRitchie

Ladies and Gentlemen:

Pursuant to Rule 14a-8(j) promulgated under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), we are writing on behalf of our client, Assembly Biosciences, Inc., a Delaware corporation (the “Company”), to request that the Staff of the Division of Corporation Finance (the “Staff”) of the U.S. Securities and Exchange Commission (the “Commission”) concur with the Company’s view that, for the reasons stated below, it may exclude the shareholder proposal and supporting statement (the “Proposal”) submitted by James McRitchie (“Mr. McRitchie”), with John Chevedden (“Mr. Chevedden”) authorized to act on Mr. McRitchie’s behalf (Mr. McRitchie and Mr. Chevedden are referred to collectively as the “Proponent”), from the proxy materials to be distributed by the Company in connection with its 2021 annual meeting of stockholders (the “2021 proxy materials”).

In accordance with Section C of Staff Legal Bulletin No. 14D (Nov. 7, 2008) (“SLB 14D”), we are emailing this letter and its attachments to the Staff at shareholderproposals@sec.gov. In accordance with Rule 14a-8(j), we are

simultaneously sending a copy of this letter and its attachments to the Proponent as notice of the Company's intent to omit the Proposal from the 2021 proxy materials.

Rule 14a-8(k) and Section E of SLB 14D provide that shareholder proponents are required to send companies a copy of any correspondence that the shareholder proponents elect to submit to the Commission or the Staff. Accordingly, we are taking this opportunity to remind the Proponent that if the Proponent submits correspondence to the Commission or the Staff with respect to the Proposal, a copy of that correspondence should concurrently be furnished to the Company.

I. The Proposal

The text of the resolution contained in the Proposal is copied below:

Resolved: Shareholders of Assembly Biosciences Inc ('Company') request the Board of Directors amend our Company's policies, articles of incorporation and/or bylaws to provide that director nominees be elected by the affirmative vote of the majority of votes cast, with a plurality vote standard retained for contested director elections, that is, when the number of director nominees exceeds the number of board seats. This proposal includes that a director who receives less than a majority vote be removed as soon as a replacement director can be qualified on an expedited basis. If such a removed director has key experience, they can transition to a consultant or director emeritus. With written justification, the board can set an effective date several years into the future for these changes to take effect.

II. Basis for Exclusion

We hereby respectfully request that the Staff concur in the Company's view that it may exclude the Proposal from the 2021 proxy materials pursuant to Rule 14a-8(i)(10) upon confirmation that the Company's Board of Directors (the "Board") has approved the Bylaw Amendment (as defined below) and the Majority Voting Policy (as defined below), which will substantially implement the Proposal.

III. Background

A. The Proposal

The Company received the Proposal, via email, on December 14, 2020, accompanied by a cover letter from Mr. McRitchie, dated December 13, 2020. On December 15, 2020, the Company sent a letter to Mr. Chevedden, via email, requesting that he provide a written statement from the record owner of Mr. McRitchie's shares verifying that Mr. McRitchie had beneficially owned the requisite number of shares of

Company common stock continuously for at least one year as of the date of submission of the Proposal (the “Deficiency Letter”). On December 16, 2020, via email, the Company received a copy of a letter from TD Ameritrade (the “Broker Letter”) verifying Mr. McRitchie’s stock ownership. Copies of the Proposal, the Deficiency Letter, the Broker Letter and related correspondence are attached hereto as Exhibit A.

B. The Anticipated Bylaw Amendment and Majority Voting Policy

Section 2.6 of the Company’s Amended and Restated Bylaws (the “Bylaws”) currently provides that the election of directors by stockholders shall be determined by a plurality of the votes properly cast on the election of directors.

The Board is expected, at a Board meeting in January 2021 (the “January Board Meeting”), to consider an amendment to the Bylaws to implement a majority voting standard for the election of directors in uncontested elections (the “Bylaw Amendment”) and an amendment to the Corporate Governance Guidelines to implement a director resignation policy applicable when an incumbent director fails to receive a majority vote (the “Majority Voting Policy”). The Bylaw Amendment will provide that each director nominee in an uncontested election shall be elected if the votes cast for such nominee’s election exceed the votes cast against such nominee’s election and that, in a contested election, the director nominees receiving a plurality of the votes cast shall be elected. In addition, the Majority Voting Policy will provide that if an incumbent director fails to receive the required vote for re-election in an uncontested election, the director must tender his or her resignation within five days following certification of the election results. Thereafter, the Nominating and Governance Committee of the Board will make a recommendation to the Board concerning whether the director’s resignation should be accepted, and under the Majority Voting Policy, the Board must take action on the recommendation within 75 days from the date of the stockholder meeting at which the election occurred.

The text of the Bylaw Amendment, marked to show the revisions, and the text of the Majority Voting Policy will be included in the supplemental letter, as described below, notifying the Staff of the Board’s action on this matter shortly after the January Board Meeting.

IV. The Proposal May be Excluded Pursuant to Rule 14a-8(i)(10) Because the Company Will Have Substantially Implemented the Proposal.

Rule 14a-8(i)(10) permits a company to exclude a shareholder proposal if the company has already substantially implemented the proposal. The Commission adopted the “substantially implemented” standard in 1983 after determining that the “previous formalistic application” of the rule defeated its purpose, which is to “avoid the possibility of shareholders having to consider matters which already have been favorably acted upon by the management.” *See* Exchange Act Release No. 34-20091

(Aug. 16, 1983) (the “1983 Release”); Exchange Act Release No. 34-12598 (July 7, 1976). Accordingly, the actions requested by a proposal need not be “fully effected” provided that they have been “substantially implemented” by the company. *See* 1983 Release.

Applying this standard, the Staff has consistently permitted the exclusion of a proposal under Rule 14a-8(i)(10) when it has determined that the company’s policies, practices and procedures or public disclosures compare favorably with the guidelines of the proposal. *See, e.g., Devon Energy Corp.* (Apr. 1, 2020)*; *Johnson & Johnson* (Jan. 31, 2020)*; *Pfizer Inc.* (Jan. 31, 2020)*; *The Allstate Corp.* (Mar. 15, 2019); *Johnson & Johnson* (Feb. 6, 2019); *United Cont’l Holdings, Inc.* (Apr. 13, 2018); *eBay Inc.* (Mar. 29, 2018); *Kewaunee Scientific Corp.* (May 31, 2017); *Wal-Mart Stores, Inc.* (Mar. 16, 2017); *Dominion Resources, Inc.* (Feb. 9, 2016); *Ryder System, Inc.* (Feb. 11, 2015); *Wal-Mart Stores, Inc.* (Mar. 27, 2014).

In addition, the Staff has permitted exclusion under Rule 14a-8(i)(10) where a company already addressed the underlying concerns and satisfied the essential objective of the proposal, even if the proposal had not been implemented exactly as proposed by the proponent. For example, in *Oshkosh Corp.* (Nov. 4, 2016), the Staff permitted exclusion under Rule 14a-8(i)(10) of a proposal asking the board to amend certain provisions of the company’s proxy access bylaw in accordance with the six “essential elements” specified in the proposal. In arguing that the proposal had been substantially implemented, the company explained that it had adopted three of the six proposed changes in the proposal, including addressing the essential objective of the proposal to expand the ability of shareholders to use proxy access by amending the minimum ownership requirement to 3% of shares rather than 5% of shares. Although the proposal asked for the adoption of all of the proposed changes, the Staff concluded that the company’s bylaw amendments “compare favorably with the guidelines of the proposal” and that the company substantially implemented the proposal. Similarly, in *Wal-Mart Stores, Inc.* (Mar. 30, 2010), the proposal requested that the company adopt six principles for national and international action to stop global warming. The company argued that its Global Sustainability Report, available on the company’s website, substantially implemented the proposal. Although the report referred to by the company set forth only four principles that covered most, but not all, of the issues raised by the proposal, the Staff concluded that the company had substantially implemented the proposal. *See, e.g., Masco Corp.* (Mar. 29, 1999) (permitting exclusion on substantial implementation grounds where the company adopted a version of the proposal with slight modifications and clarification as to one of its terms); *see also, e.g., The Wendy’s Co.* (Apr. 10, 2019) (permitting exclusion on substantial implementation grounds of a proposal requesting a report assessing human rights risks of the company’s operations, including the principles and methodology used to make the assessment, the

* Citations marked with an asterisk indicate Staff decisions issued without a letter.

frequency of assessment and how the company would use the assessment's results, where the company had a code of ethics and a code of conduct for suppliers and disclosed on its website the frequency and methodology of its human rights risk assessments); *MGM Resorts International* (Feb. 28, 2012) (permitting exclusion on substantial implementation grounds of a proposal requesting a report on the company's sustainability policies and performance, including multiple objective statistical indicators, where the company published an annual sustainability report); *Exelon Corp.* (Feb. 26, 2010) (permitting exclusion on substantial implementation grounds of a proposal requesting a report disclosing policies and procedures for political contributions and monetary and non-monetary political contributions where the company had adopted corporate political contributions guidelines).

The text of the Proposal, including numerous references in the supporting statement, makes clear that the Proposal's essential objective is to "transition from a plurality vote standard to a majority vote standard when only board nominated candidates are on the ballot." Applying the principles described above, the Staff consistently has permitted exclusion under Rule 14a-8(i)(10) of proposals, substantially similar to the Proposal, where a company has implemented a majority voting standard for uncontested director elections. *See, e.g., AECOM* (Dec. 21, 2018); *Kellogg Co.* (Dec. 27, 2017); *Genomic Health, Inc.* (Mar. 13, 2015); *3D Systems Corp.* (Jan. 21, 2015); *Edison Int'l* (Dec. 23, 2010); *Symantec Corp.* (June 3, 2010); *The Dow Chemical Co.* (Mar. 3, 2008); *American Insurance Group, Inc.* (Mar. 12, 2008); *Citigroup Inc.* (Mar. 8, 2007); *AT&T Inc.* (Jan. 18, 2007) (each permitting exclusion of a proposal under Rule 14a-8(i)(10) where the company had amended or agreed to amend its bylaws to provide for a majority voting standard in uncontested director elections).

The Staff also has consistently permitted exclusion under Rule 14a-8(i)(10) where a company has implemented a majority voting standard for uncontested director elections in its bylaws and has adopted a separate majority voting or director resignation policy to address the treatment of a "holdover director," including where the resignation process does not entirely align with the process contained in the proposal. For example, in *AECOM* (Dec. 21, 2018), the company adopted a majority voting bylaw amendment and amended its corporate governance guidelines to implement a resignation policy that is substantially similar to the Company's anticipated Majority Voting Policy. Similar to the Proposal, in that instance, the proposal's resolved clause also requested that "a director who receives less than such a majority vote be removed from the board immediately or as soon as a replacement director can be qualified on an expedited basis." Even though the company's resignation policy may not have been exactly as envisaged by the proponent, the Staff nonetheless permitted exclusion under Rule 14a-8(i)(10) and noted that "the [c]ompany's bylaws compare favorably with the guidelines of the [p]roposal and that the [c]ompany has, therefore, substantially implemented the [p]roposal." Similarly, in *3D Systems Corp.* (Jan. 21, 2015), the company adopted a majority voting bylaw amendment and amended its corporate governance guidelines to

implement a resignation policy that is substantially similar to the one set forth in the Company's anticipated Majority Voting Policy. In that instance, the proponent objected to the company's resignation policy, but the Staff nonetheless permitted exclusion under Rule 14a-8(i)(10) and noted that "[the company's] bylaws compare favorably with the guidelines of the proposal and that [the company] has, therefore, substantially implemented the proposal." *See also, e.g., Kellogg Co.* (Dec. 27, 2017); *Genomic Health, Inc.* (Mar. 13, 2015); *American Insurance Group, Inc.* (Mar. 12, 2008).

As in the foregoing letters, the anticipated Bylaw Amendment and Majority Voting Policy substantially implement the Proposal. Specifically, in the event that the Board adopts the Bylaw Amendment and Majority Voting Policy, the Company will have implemented a majority voting standard for uncontested director elections (rather than a plurality voting standard) and will have provided that an incumbent director who fails to receive majority support must promptly tender his or her resignation from the Board. Therefore, the Company will have addressed the essential objective of the Proposal.

We submit this no-action request now to address the timing requirements of Rule 14a-8(j). We will submit a supplemental letter notifying the Staff of the Board's action on this matter, which will include a copy of the Bylaw Amendment and Majority Voting Policy approved by the Board, shortly after the January Board Meeting. The Staff consistently has permitted exclusion under Rule 14a-8(i)(10) where a company has notified the Staff that its board of directors is expected to take certain action that will substantially implement the proposal and then supplements its request for no-action relief by notifying the Staff after that action has been taken by the board of directors. *See, e.g., Fortive Corp.* (Feb. 12, 2020)*; *AbbVie Inc.* (Feb. 27, 2019); *AbbVie Inc.* (Feb. 16, 2018); *The Southern Co.* (Feb. 24, 2017); *Visa Inc.* (Nov. 14, 2014); *Hewlett-Packard Co.* (Dec. 19, 2013); *Starbucks Corp.* (Nov. 27, 2012) (each permitting exclusion of a proposal under Rule 14a-8(i)(10) where the board of directors was expected to take action that would substantially implement the proposal, and the company supplementally notified the Staff of the board action).

Accordingly, the Company believes that once the Board takes the actions described above, the Proposal will have been substantially implemented and may be excluded under Rule 14a-8(i)(10).

V. Conclusion

Based upon the foregoing analysis, the Company respectfully requests that the Staff concur that it will take no action if the Company excludes the Proposal from its 2021 proxy materials. Should the Staff disagree with the conclusions set forth in this letter, or should any additional information be desired in support of the Company's position, we would appreciate the opportunity to confer with the Staff concerning these


Office of Chief Counsel

January 15, 2021

Page 7

matters prior to the issuance of the Staff's response. Please do not hesitate to contact the undersigned at (202) 371-7233.

Very truly yours

A handwritten signature in blue ink, appearing to read "Marc S. Gerber", written in a cursive style.

Marc S. Gerber

Enclosures

cc: Jason Okazaki
Chief Legal and Business Officer, Corporate Secretary
Assembly Biosciences, Inc.

John Chevedden

EXHIBIT A

(see attached)

Corporate Governance

CorpGov.net: improving accountability through democratic corporate governance since 1995

Elizabeth H. Lacy
Corporate Secretary
Assembly Biosciences, Inc.
11711 N. Meridian Street, Suite 310
Carmel, IN 46032
Phone: 1-855-971-4467
elizabeth@assemblybio.com

Dear Corporate Secretary,

I am submitting the attached shareholder proposal for a vote at the next annual shareholder meeting to **Transition to Elect Directors by Majority Vote**.

The proposal meets all Rule 14a-8 requirements, including the continuous ownership of the required stock value for over a year. I pledge to continue to hold stock until after the date of the next shareholder meeting. My submitted format, with the shareholder-supplied emphasis, is intended to be used for definitive proxy publication.

This letter confirms that we are delegating John Chevedden to act as our agent regarding this Rule 14a-8 proposal, including its submission, negotiations and/or modification, and presentation at the forthcoming shareholder meeting. Please direct all future communications regarding our rule 14a-8 proposal to John Chevedden ***

to facilitate prompt communication. Please identify James McRitchie as the proponent of the proposal exclusively.

Your consideration and the consideration of the Board of Directors is appreciated in responding to this proposal. We expect to forward a broker letter soon, so if you simply acknowledge our proposal in an email message to *** , it may not be necessary for you to request such evidence of ownership.

Sincerely,



James McRitchie

December 13, 2020

Date

[ASMB: Rule 14a-8 Proposal, December 13, 2020
[This line and any line above it – *Not* for publication.]
Proposal [4] – Transition to Elect Directors by Majority Vote

Resolved: Shareholders of Assembly Biosciences Inc ('Company') request the Board of Directors amend our Company's policies, articles of incorporation and/or bylaws to provide that director nominees be elected by the affirmative vote of the majority of votes cast, with a plurality vote standard retained for contested director elections, that is, when the number of director nominees exceeds the number of board seats. This proposal includes that a director who receives less than a majority vote be removed as soon as a replacement director can be qualified on an expedited basis. If such a removed director has key experience, they can transition to a consultant or director emeritus. With written justification, the board can set an effective date several years into the future for these changes to take effect.

Supporting Statement: To provide shareholders a meaningful role in director elections, our Company's current director election standard should transition from a plurality vote standard to a majority vote standard when only board nominated candidates are on the ballot.


Under our Company's current voting system, a director can be elected if all shareholders oppose the director but one shareholder votes FOR, even by mistake. More than 90% of the companies in the S&P 500 have adopted majority voting for uncontested elections.

In 2019 and 2020 majority shares voted FOR similar proposals at TG Therapeutics, Lipocine, Abeona Therapeutics, Alico, Guidewire Software, Stemline Therapeutics, Caesars Entertainment, RadNet, Gannett, New Residential Investment, Safety Insurance Group, First Community Bancshares, Greenhill, and Advaxis.

Vanguard includes the following in their proxy voting guidance: "If the company has plurality voting, a fund will typically vote for shareholder proposals requiring majority vote for election of directors." BlackRock's proxy voting guidelines include the following: "Majority voting standards assist in ensuring that directors who are not broadly supported by shareholders are not elected to serve as their representatives." Many of our other large shareholders have similar proxy voting policies.

Our board is locked into an outdated governance structure that reduces accountability to shareholders, increasing the likelihood of stagnation. We should not risk *Zombies on Board: Investors Face the Walking Dead* (<https://www.msci.com/www/blog-posts/zombies-on-board-investors-face/02161045315>).

**To Enhance Shareholder Value, Vote FOR
Elect Directors by Majority Vote – Proposal [4]**



[This line and any below are *not* for publication]
Number 4* to be assigned by Company

The graphic above is intended to be published with the rule 14a-8 proposal. The graphic would be the same size as the largest management graphic (and accompanying bold or highlighted management text with a graphic) or any highlighted management executive summary used



in conjunction with a management proposal or a rule 14a-8 shareholder proposal in the 2021 proxy.

The proponent is willing to discuss the in unison elimination of both shareholder graphic and management graphic in the proxy in regard to specific proposals.

Reference: SEC Staff Legal Bulletin No. 14I (CF)

[16] Companies should not minimize or otherwise diminish the appearance of a shareholder's graphic. For example, if the company includes its own graphics in its proxy statement, it should give similar prominence to a shareholder's graphics. If a company's proxy statement appears in black and white, however, the shareholder proposal and accompanying graphics may also appear in black and white.

Notes: This proposal is believed to conform with Staff Legal Bulletin No. 14B (CF), September 15, 2004 including (emphasis added):

Accordingly, going forward, we believe that it would not be appropriate for companies to exclude supporting statement language and/or an entire proposal in reliance on rule 14a-8(i)(3) in the following circumstances:

- the company objects to factual assertions because they are not supported;
- the company objects to factual assertions that, while not materially false or misleading, may be disputed or countered;
- the company objects to factual assertions because those assertions may be interpreted by shareholders in a manner that is unfavorable to the company, its directors, or its officers; and/or
- the company objects to statements because they represent the opinion of the shareholder proponent or a referenced source, but the statements are not identified specifically as such.

We believe that it is appropriate under rule 14a-8 for companies to address these objections in their statements of opposition.

See also Sun Microsystems, Inc. (July 21, 2005)

The stock supporting this proposal will be held until after the annual meeting and the proposal will be presented at the annual meeting. Please acknowledge this proposal promptly by email ***



December 15, 2020

By Email ***

John Chevedden

Re: Notice of Defect – Stockholder Proposal

Dear Mr. Chevedden:

On December 14, 2020 at 7:43 a.m. Pacific Time, we received your email, which transmitted a stockholder proposal (the "Proposal") proposed by James McRitchie for inclusion in the proxy materials for the 2021 Annual Meeting of Stockholders (the "Annual Meeting") of Assembly Biosciences, Inc. (the "Company"). In a letter accompanying the Proposal, Mr. McRitchie appointed you as his agent to submit, negotiate, modify and present at the Annual Meeting the Proposal on his behalf. The purpose of this letter is to inform you that the submission does not comply with Rule 14a-8 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and therefore is not eligible for inclusion in our proxy statement for the Annual Meeting. SEC regulations require us to bring this deficiency to your attention.

Rule 14a-8(b) provides that, to be eligible to submit a stockholder proposal, a proponent must have continuously held a minimum of \$2,000 in market value, or 1 %, of the Company's securities entitled to be voted on the proposal for at least one year prior to the date the proposal is submitted. Mr. McRitchie has not provided any proof that he has continuously held, for the one-year period preceding and including the date the Proposal was submitted to us (December 14, 2020), shares of our common stock having at least \$2,000 in market value or representing at least 1 % of the outstanding shares of our common stock. Furthermore, our records do not list Mr. McRitchie as a record holder of our common stock. Because Mr. McRitchie is not a record holder of our common stock, he may substantiate his ownership in either of two ways:

1. he may provide a written statement from the record holder of the shares of our common stock beneficially owned by him, verifying that, on December 14, 2020, when you submitted the Proposal on his behalf, he had continuously held, for at least one year, the requisite number or value of shares of our common stock; or
2. he may provide a copy of a filed Schedule 13D, Schedule 13G, Form 3, Form 4 or Form 5, or any amendment to any of those documents or updated forms, reflecting ownership of the requisite number or value of shares of our common stock as of or before the date on which the one-year eligibility period began, together with a written statement that he has continuously held the shares for the one-year period as of the date of the statement.

The staff of the SEC's Division of Corporation Finance has provided guidance to assist companies and stockholders with complying with Rule 14a-8(b)'s eligibility criteria. This guidance, contained in Staff Legal Bulletin No. 14F (October 18, 2011) and Staff Legal Bulletin No. 14G (October 16, 2012), clarifies that proof of ownership for Rule 14a-8(b) purposes must be provided by the "record holder" of the securities, which is either the person or entity listed on the Company's stock records as the owner of

the securities or a Depository Trust Company (“DTC”) participant (or an affiliate of a DTC participant). A proponent who is not a record owner must therefore obtain the required written statement from the DTC participant through which the proponent’s securities are held. If a proponent is not certain whether its broker or bank is a DTC participant, the proponent may check the DTC’s participant list, which is currently available at <http://www.dtcc.com/~media/Files/Downloads/client-center/DTC/alpha.pdf>. If the broker or bank that holds the proponent’s securities is not on DTC’s participant list, the proponent will need to obtain proof of ownership from the DTC participant through which its securities are held. If the DTC participant knows the holdings of the proponent’s broker or bank, but does not know the proponent’s holdings, the proponent may satisfy the proof of ownership requirement by obtaining and submitting two proof of ownership statements verifying that, at the time the proposal was submitted, the required number or value of securities had been continuously held by the proponent for at least one year preceding and including the date of submission of the proposal, with one statement from the proponent’s broker or bank confirming the required ownership, and the other statement from the DTC participant confirming the broker or bank’s ownership.

For the Proposal to be eligible for inclusion in our proxy materials for the Annual Meeting, the information requested above must be furnished to us electronically or be postmarked no later than 14 calendar days from the date you receive this letter. If the information is not provided, we may exclude the Proposal from our proxy materials pursuant to Rule 14a-8(f). Please address any response to me at John O. Gunderson, Senior Director, Corporate & SEC Counsel and Assistant Secretary, Assembly Biosciences, Inc., 331 Oyster Point Blvd., Fourth Floor, South San Francisco, California 94080 or jgunderson@assemblybio.com.

In accordance with SEC Staff Legal Bulletin Nos. 14 and 14B, a copy of Rule 14a-8, including Rule 14a-8(b), is enclosed for your reference. Also enclosed for your reference is a copy of Staff Legal Bulletin Nos. 14F and 14G. Please acknowledge receipt of this letter promptly by email to elizabeth@assemblybio.com.

Very truly yours,



John O. Gunderson
Senior Director, Corporate & SEC Counsel and Assistant Secretary

Enclosures

cc: Jason A. Okazaki, Chief Legal and Business Officer and Corporate Secretary



12/16/2020

James Mcritchie

Re: Your TD Ameritrade Account Ending in ***

Dear James Mcritchie,

Pursuant to your request, this letter is to confirm that as of the date of this letter, James McRitchie held and had held continuously for at least 13 months, 200 common shares of Assembly Biosciences Inc (ASMB) in an account ending i *** at TD Ameritrade. The DTC clearinghouse number for TD Ameritrade is 0188.

If we can be of any further assistance, please let us know. Just log in to your account and go to the Message Center to write us. You can also call Client Services at 800-669-3900. We're available 24 hours a day, seven days a week.

Sincerely,

A handwritten signature in cursive script that reads 'Gabriel Elliott'.

Gabriel Elliott
Resource Specialist
TD Ameritrade

This information is furnished as part of a general information service and TD Ameritrade shall not be liable for any damages arising out of any inaccuracy in the information. Because this information may differ from your TD Ameritrade monthly statement, you should rely only on the TD Ameritrade monthly statement as the official record of your TD Ameritrade account.

Market volatility, volume, and system availability may delay account access and trade executions.

TD Ameritrade, Inc., member FINRA/SIPC (www.finra.org , www.sipc.org). TD Ameritrade is a trademark jointly owned by TD Ameritrade IP Company, Inc. and The Toronto-Dominion Bank. © 2015 TD Ameritrade IP Company, Inc. All rights reserved. Used with permission.